Acclarent is engaged in the development of ENT procedures with a portfolio comprising balloon technologies for sinus dilation, eustachian tube dilation, and surgical navigation systems
Integra LifeSciences has entered into an agreement to acquire Acclarent. (Credit: Anthony Camerlo on Unsplash)
Integra LifeSciences has agreed to acquire Acclarent from Johnson & Johnson MedTech’s subsidiary Ethicon for $275m in an all-cash deal.
The consideration is subject to standard purchase price adjustments, with an additional $5 million payable upon achieving specific regulatory milestones.
Based in California, Acclarent is engaged in the development of ear, nose, and throat (ENT) procedures.
Its portfolio includes balloon technologies for sinus dilation, eustachian tube dilation, and surgical navigation systems.
The ENT company operates research and development (R&D) facilities in Irvine and Haifa, Israel, and uses third-party manufacturers.
Integra LifeSciences president and CEO Jan De Witte said: “This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment.
“Acclarent’s culture of pioneering technologies aligns with Integra’s legacy of innovation to transform care and restore patients’ lives.”
Acclarent will be integrated into Integra’s Codman Specialty Surgical (CSS) division after the closing of the deal.
The deal is expected to enable Integra LifeSciences in becoming a major provider of ENT products and technologies. Currently, the company offers the MicroFrance line of instruments in this ENT category.
Integra LifeSciences CSS president Mike McBreen said: “The ENT segment is an anatomical adjacency to neurosurgery. For example, this acquisition will provide opportunities for ENT and neurosurgeons to closely collaborate on tumour care using skull base approaches.
“Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, allowing us to deliver future innovation not only within ENT, but also across our other CSS technology platforms.”
The transaction is expected to be completed by Q2 of 2024, subject to usual closing conditions and regulatory clearances.
Integra LifeSciences’ exclusive financial advisor for the deal is Goldman, Sachs & Co., and its exclusive legal advisor is Morgan, Lewis & Bockius.